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S UMMA R Y
BACKGROUND : Anaemia commonly complicates both
human immunodeficiency virus (HIV) infection and
tuberculosis (TB), contributing substantially to morbid-
ity and mortality. The mechanisms underlying anaemia
and corresponding treatments in co-infected patients are
poorly defined.
OB J E C T I V E : To determine the relative contributions of
anaemia of chronic disease (ACD) and iron deficiency to
anaemia in patients with HIV-associated TB.
DE S I GN : Consecutively recruited hospitalised (n¼102)
and matched ambulatory patients (n ¼ 51) with
microbiologically confirmed HIV-associated TB in Cape
Town, South Africa, were included. Haemoglobin levels,
iron status markers, hepcidin and pro-inflammatory
cytokines in blood were measured. We determined the
prevalence of ACD and iron-deficiency anaemia (IDA)
using seven different published definitions of IDA.
R E SU LT S : More than 80% of enrolled HIV-associated
TB patients were anaemic, and anaemia was more severe
among in-patients. Over 95% of anaemic HIV-associat-
ed TB patients had ACD, whereas the proportion with
IDA using a range of seven different definitions was low
overall (median ,3%, range 0–32.6) in both patient
groups. The proportion with IDA and hepcidin concen-
tration 620.0 ng/ml (predictive of responsiveness to
oral iron supplementation) was also very low (median
,3%, range 0–15.1).
CON C L U S I O N S : ACD was the predominant cause
underlying anaemia in HIV-associated TB patients,
and IDA was very uncommon in this setting. The
majority of anaemic HIV-associated TB patients were
unlikely to benefit from oral iron supplementation.
K E Y WORD S : human immunodeficiency virus; AIDS;
tuberculosis; Africa; anaemia; mechanism; iron; hepci-
din
NEARLY ONE THIRD OF THE WORLD’S popu-
lation is anaemic, and in sub-Saharan Africa the
prevalence of anaemia ranges from 34% to 62%
across the continent.1 Anaemia may be associated
with fatigue, decreased cognitive ability and produc-
tivity and, therefore, poorer quality of life. In 2010,
anaemia accounted for more than 17 million years of
life lived with disability (YLDs) in sub-Saharan Africa
alone.1
While the aetiology of anaemia in sub-Saharan
Africa is context-specific and multifactorial in nature,
HIV and tuberculosis (TB) are both strongly associ-
ated with anaemia.2–6 The high prevalence of
anaemia in patients with HIV and/or TB is associated
not only with substantial morbidity,7 but also with
increased risk of mortality.2,3,8,9 However, defining
appropriate therapeutic interventions is hampered by
the lack of data characterising the underlying
mechanisms of anaemia. Increasing evidence suggests
that the majority of patients with TB and HIV-
associated TB have anaemia of chronic disease (ACD)
with or without an additional contributing aetiolo-
gy.4,5,10 Improved insights into the mechanisms
underlying anaemia in patients with HIV-associated
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TB may allow for more effective interventions to be
devised.
We have previously reported that blood concen-
trations of hepcidin, a key regulator of iron homeo-
stasis and the hormone that is central to the
pathogenesis of ACD, were strongly associated with
both the severity of anaemia as well as the degree of
mycobacterial dissemination in patients with HIV-
associated TB.11 We thus hypothesised that ACD
would be the most common cause of anaemia in such
patients, although this has not previously been
systematically characterised in patients with HIV-
associated TB.
The present study was undertaken to characterise
the relative contributions of ACD, iron-deficiency
anaemia (IDA) and both combined (ACDþIDA) to
anaemia in patients with HIV-associated TB. We also
determined the prevalence of IDA according to a
range of seven different published definitions for
IDA.4,12–16 Finally, as high hepcidin concentrations
have strong predictive value for non-responsiveness
to oral iron therapy,17 we determined the proportion
of HIV-associated TB patients who had both IDA and
low hepcidin concentrations, as this defines a patient
subgroup that may benefit from oral iron supplemen-
tation during their treatment course.
METHODS
HIV-infected hospital in-patients with newly diag-
nosed TB and ambulatory antiretroviral therapy
(ART) naı¨ve out-patients with TB were included.
Patients were prospectively recruited as part of two
previously reported TB diagnostics studies.18,19 They
predominantly resided in township communities of
Cape Town, South Africa, where there is a well-
described large burden of HIV-associated TB.20
Written informed consent was provided by all
patients, and both parent studies were approved by
the research ethics committees of the University of
Cape Town, Cape Town, South Africa, and the
London School of Hygiene & Tropical Medicine,
London, UK.
Hospitalised patients were selected from among
HIV-infected adults aged 718 years requiring acute
admission to the medical wards at G F Jooste
Hospital, Cape Town, South Africa, who, regardless
of their presenting symptomatology, were recruited to
participate in a study of rapid microbiological
screening for TB.19 Patients were eligible for inclusion
in the present study if they had a new microbiolog-
ically proven TB diagnosis, a frozen plasma sample
available and had not received a blood transfusion
within the preceding 120 days (the approximate life
span of red blood cells). Those who had previously
started ART but were not currently on ART due to
interruption for any reason were excluded to reduce
the heterogeneity of included patients.
Ambulatory out-patients with HIV-associated TB
were also included to allow for the determination of
whether anaemia prevalence and ACD or IDA
differed across the spectrum of disease severity.
Patients were selected from among ART-naı¨ve, HIV-
infected adults (age 718 years) presenting for
initiation of ART at the Hannan Crusaid HIV Centre
in Gugulethu Township, Cape Town, South Africa.18
Those eligible were patients with a new microbiolog-
ical diagnosis of TB established during systematic
microbiological screening and who had a frozen
serum sample available. Hospitalised and ambulatory
patient groups were matched (2:1) on the basis of age
(61 year), sex and CD4 counts (625 cells/ll), but not
haemoglobin (Hb) levels.
Procedures
Demographic and clinical details were obtained from
all study participants in each patient group, and
clinical samples were obtained for TB investigations
as previously described.18,19 A venous blood sample
was obtained from all patients to permit additional
laboratory measurements, and plasma or serum was
stored at 808C. Multiple microbiological tests for
TB were undertaken on respiratory and non-respira-
tory samples from both patient groups, as described
previously.11,18,19
At the time of hospital admission or at the first
clinic visit (before starting ART), full blood counts
(including Hb concentrations), iron status markers
(iron, ferritin and transferrin concentrations), creat-
inine, plasma viral load and blood CD4 counts were
measured at the National Health Laboratory Service
(NHLS) in Cape Town. The results of all laboratory
measurements and mycobacterial investigations were
extracted from the NHLS computerised data system.
Stored plasma or serum samples from all patients
were tested to determine levels of C-reactive protein
(CRP) using the human CRP Quantikine ELISA
(R&D Systems, Minneapolis, MN, USA); erythro-
poietin (EPO) levels were measured using Quantikine
IVD Human Erythropoietin ELISA (R&D Systems);
soluble transferrin receptor (sTfR) levels were mea-
sured using the Quantikine IVD Human sTfR ELISA;
hepcidin concentrations were measured using the
Hepcidin-25 bioactive ELISA (DRG Instruments,
Marburg, Germany); and pro-inflammatory cyto-
kines (interleukin [IL] 1b, IL-6, interferon gamma
[IFN-c] and tumour necrosis factor alpha [TNF-a])
were measured using the Bio-Plex Precision Pro
Human Cytokine 10-Plex Panel (Bio-Rad Laborato-
ries, Hercules, CA, USA). All assays were approved
for use on both serum and plasma samples, per-
formed in strict accordance with the manufacturer’s
instructions, and clinical specimens were processed
according to standardised protocols and quality
assurance procedures at centralised laboratories.18,19
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Definitions and statistical analysis
A new diagnosis of TB was defined by the detection
Mycobacterium tuberculosis in any clinical sample
(sputum or non-respiratory sample) using culture
and/or the Xpertw MTB/RIF assay (Cepheid, Sunny-
vale, CA, USA). Patients with evidence of non-
tuberculous mycobacterial infection were excluded.
World Health Organization (WHO) criteria were
used to classify the severity of anaemia:21 no anaemia
(Hb 713.0 g/dl for males, 712.0 g/dl for females),
mild anaemia (11.0–12.9 g/dl for males, 11.0–11.9 g/
dl for females), moderate anaemia (8.0–10.9 g/dl for
males and females) or severe anaemia (,8.0 g/dl for
males and females). Patients with anaemia were then
classified into one of three mutually exclusive groups
according to a published algorithm:13,22 ACD, IDA
or combined ACD and IDA (ACDþIDA) (Figure 1A).
IDA prevalence was further explored using multiple
previously published definitions of IDA (Figure
1B).4,12–16 An elevated hepcidin concentration was
defined as .20 ng/ml, as this cut-off has previously
shown good utility for predicting non-responsiveness
to oral iron therapy among patients with IDA.17
Estimated glomerular filtration rates (eGFR) were
calculated using the Modification of Diet in Renal
Disease (MDRD) Study equation.23 v2 tests or
Fisher’s exact tests were used to compare proportions,
and Wilcoxon rank-sum or Kruskal-Wallis tests were
used to compare medians. All statistical tests were
two-sided at a¼ 0.05.
RESULTS
Of 139 potentially eligible medical in-patients with
newly diagnosed TB, 8 did not have a plasma sample
available for additional laboratory measurements and
29 were ineligible as they had received a blood
transfusion within the previous 120 days (n¼ 15) or
had interrupted ART (n ¼ 14). A final 102 hospital-
ised patients with HIV-associated TB were included
in the study, and exactly half the number of matched
ambulatory ART-naı¨ve patients with HIV-associated
TB (n ¼ 51) were also included. Due to patient
matching, the median age (33.2 years, interquartile
range [IQR] 27.7–40.8 vs. 33.4, IQR 28.2–42.4, P¼
0.992), sex distribution (64.7% male vs. 64.7%
female, P ¼ 1.0) and median CD4 cell counts (102
cells/ll, IQR 35–212 vs. 102 cells/ll, IQR 42–186, P
¼ 0.718) were similar between the two TB patient
groups.
Prevalence of anaemia and baseline characteristics
The prevalence rates of anaemia in the hospitalised
and ambulatory groups of HIV-associated TB pa-
tients were very high but similar (86.3% vs. 84.3%,
respectively), although anaemia was typically of
greater severity in hospitalised patients (Figure 2).
The baseline characteristics for each patient popula-
tion stratified according to anaemia severity classifi-
cation are shown in Tables 1 and 2. In both
populations, a number of variables were associated
with greater severity of anaemia, including lower
CD4 cell counts and higher HIV viral loads (Table 1).
Strong graded associations were also observed
between greater anaemia severity and lower mean
corpuscular Hb (MCH) levels, lower transferrin
concentrations as well as higher ferritin, hepcidin
and erythropoietin concentrations (Table 2). Inflam-
matory markers associated with greater severity of
anaemia in both patient groups included increasing
CRP, IL-1b and IL-6 concentrations (Table 2).
Figure 1 Anaemia case definitions among patients with
human immunodeficiency virus associated tuberculosis: A)
algorithm for classifying ACD, IDA and combined ACDþIDA.
For example, a patient may be classified as having ACD only in
one of three different ways: 1) having a ferritin concentration
.336.2 ng/ml; 2) having a ferritin concentration of 30–336.2
ng/ml AND a sTfR index [sTfr/log10(ferritin)],1.0; and iii) having
a ferritin concentration of 30–336.2 ng/ml AND a sTfR index of
1.0–2.0 AND a hepcidin concentration .20.0 ng/ml. Figure
adapted from Weiss et al.13 and Cullis.22 B) Different published
definitions for IDA.* Local reference value from the National
Health Laboratory Service for the upper limit of normal range for
ferritin concentrations. The authors encourage that when
possible, local references should be utilised. †CRP-containing
index was calculated as follows: (0.34þ0.00433 ferritin [2.7
3 TfR] ‚ ferritin þ 0.0696 3 CRP þ 0.05 3 TfR).‡ sTfr index
calculated as: sTfR/log10(ferritin). HB ¼ haemoglobin; sTfR ¼
soluble transferrin receptor; IDA¼ iron deficiency anaemia; ACD
¼ anaemia of chronic disease; CRP¼ C-reactive protein.
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Classification of types of anaemia
We then restricted the analysis to those with (any)
anaemia, who were categorised into three mutually
exclusive groups according to the underlying type of
anaemia (ACD, IDA or ACDþICD combined). All
patients with anaemia had a component of ACD
(100%), and the proportion classified as having
ACDþIDA was 2.0% in hospitalised patients and
7.0% in ambulatory patients; no patients had
evidence of IDA alone.
Prevalence of iron deficiency anaemia and those with
elevated hepcidin levels
In the absence of bone marrow aspirates, we sought
to determine the differences in IDA prevalence when
a range of different published definitions for IDA was
applied (Figure 1B). We then defined what proportion
of those with IDA did not have elevated hepcidin
levels (.20 ng/ml) and might therefore possibly
benefit from oral iron therapy (Figure 3). Among
hospitalised patients with HIV-associated TB, the
proportion with IDA tended to be low—median
2.4% (range 0–32.6), except when definitions based
simply on microcytosis (mean corpuscular volume
,80 fl) or hypochromia (mean corpuscular haemo-
globin concentration ,32%) were used. Definitions
associated with a higher prevalence of IDA also
tended to include a larger proportion of patients with
elevated hepcidin levels. The overall proportion of
patients who may immediately benefit from oral iron
supplementation based upon hepcidin levels was very
low (median 2.4%, range 0–15.1). Similar patterns
were observed among ambulatory patients, where the
overall prevalence of IDA across the seven definitions
was low (median 0%, range 0–32.6), except among
those with IDA defined simply according to micro-
cytosis. Again, the proportion of those with IDA and
without elevated hepcidin levels was also very small
(median 0%, range 0–14.0). However, using the most
inclusive estimate, only 15% of patients in either
group might immediately benefit from oral iron
supplementation.
DISCUSSION
In this study of patients with HIV-associated TB
receiving care in two different clinical settings in Cape
Town, ACD was present in all anaemic patients.
While IDA prevalence varied when different defini-
tions were applied, overall IDA prevalence in both TB
groups remained low, regardless of the definition
used. The proportion of those with IDA but with low
hepcidin concentrations was even lower still. This
study therefore suggests that in this setting oral iron
supplementation is unlikely to benefit the majority of
patients with HIV-associated TB, especially prior to
starting combined ART and TB treatment.
In both TB groups, ACD alone was present in more
than 90% of anaemic patients, and in combination
with IDA in the small number of remaining anaemic
patients. This builds upon previous work in other
settings that also suggested that ACD is the predom-
inant mechanism of anaemia among TB patients with
and without HIV co-infection.4,5,10 That ACD is the
most important mechanism underlying anaemia in
HIV-associated TB was further suggested by strong
associations between greater anaemia severity and
decreasing transferrin concentrations, increasing fer-
ritin and hepcidin concentrations as well as higher
concentrations of pro-inflammatory cytokines and
CRP—consistent with the known cytokine and iron-
status marker profile of ACD.13 During active TB
disease, pro-inflammatory cytokines are upregulated;
notably, IL-6 stimulates not only CRP but also
hepcidin synthesis (the key hormone responsible for
iron homeostasis) by hepatocytes.24 Hepcidin in turn
causes internalisation and degradation of ferroportin
(the only known cellular iron efflux channel) in
reticuloendothelial cells and duodenal enterocytes.25
By restricting the availability of iron for ongoing
erythropoiesis and inhibiting the absorption of
dietary iron or oral supplements, hepcidin drives the
process of ACD during ongoing inflammation sec-
ondary to active TB disease.13 In patients with HIV-
associated TB, higher mycobacterial burden and
more disseminated disease is associated with increas-
ing hepcidin concentrations and, likely as a down-
stream consequence, more severe anaemia.11 Higher
hepcidin concentrations also strongly predict short-
Figure 2 The prevalence and severity of anaemia in hospital-
ised (n ¼ 102) and ambulatory (n ¼ 51) patients with human
immunodeficiency virus associated tuberculosis. Anaemia se-
verity was classified according to World Health Organization
criteria: no anaemia (haemoglobin713.0 g/dl for males,712.0
g/dl for females), mild anaemia (11.0–12.9 g/dl for males, 11.0–
11.9 g/dl for females), moderate anaemia (8.0–10.9 g/dl for
males and females) or severe anaemia (,8.0 g/dl for males and
females). Median haemoglobin level in hospitalised patients: 8.8
d/gl (IQR 7.2–10.8) compared to 10.6 g/dl (IQR 8.6–11.7) in
ambulatory patients (P¼ 0.004). IQR¼ interquartile range.
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term mortality in these patients.11 It is, however,
reassuring that anti-tuberculosis treatment with or
without ART is associated with normalisation of pro-
inflammatory cytokines,26 as well as hepcidin,4 and,
for the majority of co-infected patients, results in the
resolution of anaemia without additional anaemia-
specific interventions.4,5,27
The relative contribution of IDA (with or without
concomitant ACD) to anaemia among both ambula-
tory and hospitalised patients with HIV-associated
TB was very small. As bone marrow aspirates, the
gold standard for diagnosing IDA, were unavailable,
we explored multiple different published definitions
for IDA using a range of red blood cell indices and
iron status biomarkers.4,12–16 Although IDA preva-
lence varied when different definitions were applied,
overall prevalence was low. While anaemia has not
previously been systematically categorised in HIV-
associated TB patients, these results are largely in
agreement with studies among TB patients in two
previous studies;4,5 however, both previous studies
reported a slightly higher prevalence of IDA, with and
without ACD. These differences might be accounted
for by several factors, including a higher local burden
of parasitic diseases, poorer local nutrition patterns,
use of different definitions of IDA (although neither
study used bone marrow aspirates) and less upregu-
lation of pro-inflammatory cytokines, as the large
majority of patients were not co-infected with HIV in
these two studies.
Many patients with HIV-associated TB and true
IDA will also have concurrent ACD, as demonstrated
in Figure 3, where several patients with IDA had
‘elevated’ hepcidin concentrations. Those with IDA
and concurrently elevated hepcidin concentrations
would not, however, be expected to derive benefit
from oral iron therapy, as hepcidin will continue to
inhibit duodenal absorption of iron until the under-
lying chronic infection (TB and/or HIV) is treated and
the accompanying pro-inflammatory host response
resolves.13,17 While oral iron supplementation is
simple, widely available and may be effective in
treating IDA when inflammatory conditions are not
present, oral iron supplementation is unlikely to be
Figure 3 The proportion of A) hospitalised (n¼88) and B) ambulatory (n¼43) anaemic patients
with human immunodeficiency virus associated tuberculosis that have IDA according to seven
different published definitions and stratified according to hepcidin concentration (620 ng/ml¼
possibly responsive to oral iron supplementation vs. hepcidin.20 ng/ml¼ likely non-responsive to
oral iron supplementation). CRP-containing index was calculated as: (0.34þ 0.00433 ferritin
[2.73 TfR] ‚ ferritinþ 0.06963 CRPþ 0.053 TfR). sTfr index calculated as: sTfR/log10(ferritin).
CRP¼C-reactive protein; Tf¼ transferrin; sTfRi¼soluble transferrin receptor index; MCHC¼mean
corpuscular haemoglobin concentration; MCV¼mean corpuscular volume; IDA¼ iron deficiency
anaemia.
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efficacious in the majority of patients with HIV-
associated TB, and may also cause harm.28 Gastro-
intestinal side effects are commonly associated with
oral iron therapy and may interfere with patients
taking their essential anti-tuberculosis treatment and/
or ART.29 Furthermore, increased dietary iron and
iron overload are associated with increased mortality
in patients with TB and/or HIV.29–33 Greater iron
availability may increase TB risk and disease pro-
gression by functioning as a readily available essential
nutrient for TB bacilli, thereby stimulating TB
growth.32 Oral iron supplementation should there-
fore not be used blindly without weighing the
potential risks and benefits; therapeutic interventions
for anaemia in such patients should prioritise early
TB diagnosis and appropriate treatment with anti-
tuberculosis treatment and ART.
A small but important proportion of patients with
HIV-associated TB may have persistent anaemia
despite combined anti-tuberculosis treatment and
ART. Both erythrocyte microcytosis27,34 (possibly
suggestive of IDA) as well as IDA4 have been
identified as risk factors for the non-resolution of
anaemia. In these patients, oral iron supplementation
(in addition to other investigations with or without
interventions) is required. A recent study reported
that hepcidin levels begin to normalise after 2 months
of anti-tuberculosis treatment, suggesting a possible
opportunity to intervene with oral iron supplemen-
tation after this time-point.4 As the prevalence of IDA
is likely to vary between settings due to several
factors, further studies from different contexts are
needed to define: 1) what proportion of patients with
TB (with and without HIV) have IDA, and 2) at what
point during anti-tuberculosis treatment hepcidin
levels normalise in these patients so that oral iron
supplementation may be effective. Because IDA
prevalence varies with the definition applied (as
evidenced by our findings), simple methods/defini-
tions for reliably identifying those with true IDA who
are likely to benefit from oral iron therapy are
needed, such as the algorithm in Figure 1A; however,
it should be noted that hepcidin concentrations are
not yet validated for routine clinical practice.
The strengths of the study are the inclusion of two
well-defined consecutively recruited and matched
patient groups with confirmed HIV-associated TB,
and the consistent results observed in both hospital-
ised and ambulatory patients (i.e., across a spectrum
of TB disease and morbidity), which improves the
generalisability of the study findings. Due to limited
patient plasma sample volume, we were unable to
systematically investigate additional aetiologies of
anaemia, including nutritional deficiencies (folate,
B12), infections, haemolysis, etc. Moreover, because
bone marrow samples were unavailable, we cannot
exclude the possibility that marrow infiltration may
have contributed to the anaemia we classified as
ACD. This was, however, likely to be uncommon, as
most anaemic patients only had a single cell line
affected and there was no evidence of leukopaenia or
thrombocytopaenia. Data on possible adverse drug
reactions contributing to anaemia were also not
available; however, no patients were receiving anti-
tuberculosis treatment at the time of enrolment, and
zidovudine use in hospitalised patients was uncom-
mon.
In conclusion, ACD was the predominant cause
underlying anaemia in patients with HIV-associated
TB. IDA was uncommon, and IDA without elevated
hepcidin levels was very uncommon, suggesting that
the majority of anaemic HIV-TB co-infected pa-
tients are unlikely to benefit from oral iron
supplementation. Interventions for anaemia in such
patients should focus on early TB diagnosis and
appropriate treatment with anti-tuberculosis treat-
ment and ART.
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R E S U M E
CONT EX T E : L’ane´mie complique fre´quemment a` la fois
l’infection par le virus de l’immunode´ficience humaine
(VIH) et la tuberculose (TB), contribuant
substantiellement a` la morbidite´ et a` la mortalite´. Les
me´canismes a` l’origine de l’ane´mie et les traitements
correspondants chez les patients co-infecte´s sont mal
de´finis.
OB J E C T I F : De´terminer les contributions respectives des
ane´mies chroniques lie´es a` une maladie (ACD) et du
de´ficit en fer a` l’ane´mie des patients atteints de TB
associe´e au VIH.
S CH E´MA : Nous avons inclus des patients conse´cutifs
recrute´s a` l’hoˆpital (n ¼ 102) et des patients apparie´s
ambulatoires (n¼ 51) au Cap, en Afrique du Sud, avec
une TB confirme´e par microbiologie et associe´e au VIH.
Le taux d’he´moglobine, les marqueurs du fer, l’hepcidine
et les cytokines pro-inflammatoires ont e´te´ mesure´es
dans le sang. Nous avons de´termine´ la pre´valence de
l’ACD et de l’ane´mie par de´ficit en fer (IDA) en utilisant
sept diffe´rentes de´finitions publie´es de l’IDA.
R E´ S U LTAT S : Plus de 80% des patients enroˆle´s atteints
de TB associe´e au VIH e´taient ane´miques, et l’ane´mie
e´tait plus prononce´e chez les patients hospitalise´s. Plus
de 95% des patients ane´miques atteints de TB associe´e
au VIH avaient une ACD, tandis que la proportion
d’IDA, en utilisant un ensemble de sept de´finitions
diffe´rentes, a e´te´ faible dans l’ensemble (proportion
me´diane ,3% ; fourchette 0–32,6) dans les deux
groupes de patients. La proportion de patients avec
une IDA et une concentration d’hepcidine620,0 ng/ml
(pre´dictive d’une re´activite´ a` une supple´mentation orale
de fer) a e´galement e´te´ tre`s faible (me´diane ,3% ;
fourchette 0–15,1).
CON C L U S I ON : L’ACD a e´te´ la cause sous-jacente
pre´dominante de l’ane´mie chez les patients atteints de
TB associe´e au VIH, et l’IDA a e´te´ tre`s peu fre´quente
dans ce contexte. La grande majorite´ des patients
ane´miques atteints de TB associe´e au VIH e´taient donc
peu susceptibles de be´ne´ficier d’une supple´mentation
orale de fer.
R E S UM E N
MARCO DE R E F E R ENC I A: Con frecuencia la anemia
complica la infeccio´n por el virus de la
inmunodeficiencia humana (VIH) y la tuberculosis
(TB) y con ello contribuye de manera considerable a la
morbilidad y la mortalidad. Los mecanismos
fundamentales de la anemia y los tratamientos
correspondientes no se encuentran bien definidos.
OB J E T I VO: Determinar la contribucio´n relativa de la
anemia por enfermedad cro´nica (ACD) y la anemia
ferrope´nica a la anemia observada en los pacientes
aquejados de TB asociada con la infeccio´n por el VIH.
M E´ TODOS: Se incluyeron en el estudio de manera
consecutiva pacientes hospitalizados con diagno´stico
confirmado bacteriolo´gicamente de TB asociada a la
infeccio´n por el VIH (n¼102) y pacientes ambulatorios
emparejados como testigos (n ¼ 51) en la Ciudad del
Cabo, en Sura´frica. Se practico´ la determinacio´n
sanguı´nea de la hemoglobina, los marcadores del
metabolismo fe´rrico, la hepcidina y las citocinas
proinflamatorias. Se determino´ la prevalencia de ACD
y anemia ferrope´nica (IDA) en conformidad con siete
definiciones publicadas de IDA.
R E SU LTADOS: Ma´s del 80% de los pacientes aquejados
de coinfeccio´n por el VIH y TB presentaban anemia y
esta fue ma´s grave en los pacientes hospitalizados. Ma´s
del 95% de los pacientes ane´micos coinfectados
presentaban ACD y la proporcio´n de IDA, segu´n las
siete definiciones diferentes, fue en general baja en
ambos grupos (mediana de la proporcio´n ,3%;
intervalo 0–32,6). La proporcio´n pacientes con IDA y
una concentracio´n de hepcidina 620,0 ng/ml (que
pronostica la respuesta a un aporte complementario de
hierro oral) tambie´n fue muy baja (mediana ,3%;
intervalo 0–15,1).
CONC LU S I O´ N: La ACD fue la causa predominante de la
anemia subyacente en los pacientes con coinfeccio´n por
el VIH y la TB y la IDA fue muy infrecuente en este
contexto. Es poco probable que la gran mayorı´a de los
pacientes coinfectados con anemia respondiese a la
administracio´n de un complemento oral de hierro.
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